Tuesday 20 March 2012

Food And Drug Administration-Renal Cell Carcinoma-Glaxosmithkline Plc-Health Regulators

Votrient shows some cancer survival gains: FDA

WASHINGTON (Reuters) - GlaxoSmithKline Plc's Votrient extended the lives of a significant number of patients suffering from an aggressive form of cancer without the disease getting worse, but the drug did not improve overall survival rates, U.S. health regulators said on Friday. Food and Drug Administration staff also said in a review document that the drug, known generically as pazopanib, has a safety profile for patients with soft-tissue sarcoma that is similar to indications for renal cell carcinoma, for which Votrient is already approved. ... read more..

No comments:

Post a Comment